Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Harshita B Gupta"'
Autor:
Tyler Curiel, Yilun Deng, Aravind Kancharla, Myrna Garcia, Haiyan Bai, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Anand V R Kornepati, Jose R Conejo-Garcia, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.Methods We per
Externí odkaz:
https://doaj.org/article/17e6b1fa8654420fb479e0007b231c94
Autor:
Yilun Deng, Aravind Kancharla, Myrna Garcia, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Tyler J Curiel, Robert S Svatek, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Chenghao Zhang, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in
Externí odkaz:
https://doaj.org/article/2a231be16e8747f5b3befb1e7bde6cde
Autor:
Tyler J. Curiel, Ratna Vadlamudi, Rong Li, Vincent Hurez, Kathrin Thedieck, Mary Jo Turk, Yang Liu, Kruthi Murthy, José Conejo-Garcia, Alvaro Padron, Justin M. Drerup, Bin Yuan, Shunhua Lao, Srilakshmi Pandeswara, Gangadhara Sareddy, Harshita B. Gupta, Curtis A. Clark
PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::654db7645d5b3a3e69a710be5c177f9f
https://doi.org/10.1158/0008-5472.c.6508806.v1
https://doi.org/10.1158/0008-5472.c.6508806.v1
Autor:
Tyler J. Curiel, Ratna Vadlamudi, Rong Li, Vincent Hurez, Kathrin Thedieck, Mary Jo Turk, Yang Liu, Kruthi Murthy, José Conejo-Garcia, Alvaro Padron, Justin M. Drerup, Bin Yuan, Shunhua Lao, Srilakshmi Pandeswara, Gangadhara Sareddy, Harshita B. Gupta, Curtis A. Clark
Suppl. Fig. 1 confirms that ID8agg is more virulent versus parental ID8 in WT mice. Suppl. Fig. 2 provides relevant details for plasmids used to make recombinant cell lines, and gives Western blot validations for each PD-L1lo clone described. Suppl,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3425089080c9fa577751c54a539adb83
https://doi.org/10.1158/0008-5472.22413750
https://doi.org/10.1158/0008-5472.22413750
Autor:
Jordan A. Naumann, Prokopios P. Argyris, Michael A. Carpenter, Harshita B. Gupta, Yanjun Chen, Nuri A. Temiz, Yufan Zhou, Cameron Durfee, Joshua Proehl, Brenda L. Koniar, Silvestro G. Conticello, David A. Largaespada, William L. Brown, Hideki Aihara, Rachel I. Vogel, Reuben S. Harris
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 11; Pages: 9305
Although the APOBEC3 family of single-stranded DNA cytosine deaminases is well-known for its antiviral factors, these enzymes are rapidly gaining attention as prominent sources of mutation in cancer. APOBEC3′s signature single-base substitutions, C
Autor:
Haiyan Bai, Alvaro S Padron, Yilun Deng, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari, Aravind Kancharla, Anand V R Kornepati, Myrna Garcia, Ryan Michael Reyes, Harshita B Gupta, Jose R Conejo-Garcia, Tyler Curiel
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e004871
BackgroundTumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.MethodsWe perfo
Autor:
Christian Cervantes, Mustafa Khan, Maria Fernandez, Zexuan Liu, Zainab Hakeem, Suryavathi Viswanadhapalli, Harshita B. Gupta, Tyler J Curiel, Hui Yan, Ratna Vadlamudi, Zhenming Xu
Publikováno v:
The Journal of Immunology. 208:112.11-112.11
The discovery that PD-L1 inhibits PD-1 on CD8+ T cells has led to new mechanistic insights into the regulation of host immune responses. The contribution of PD-L1 expressed by different immune cell types remains poorly understood, partly due to the l
Autor:
Yilun Deng, Justin Michael Drerup, Xinyue Zhang, Ryan M Reyes, Jenny Mendez, Miro E Raeber, Myrna G Garcia, Alvaro S Pardon, Harshita B. Gupta, Onur Boyman, Tyler J Curiel
Publikováno v:
The Journal of Immunology. 206:57.17-57.17
Regulatory T cells (Treg) engage IL-2 by high affinity CD25, and anti-tumor effector T cells (Teff) use intermediate affinity CD122. We studied IL-2 complexes (IL-2c) that selectively activate CD122+ Teff over CD25+ Tregs. We found IL-2c but not aPD-
Autor:
Anand V Kornepati, Yilun Deng, Eloise Dray, Clare Murray, Suresh C Kari, Erica Osta, Zexuan Liu, Jacob Boyd, Alvaro Padron, Ryan Reyes, Harshita B. Gupta, Curtis A Clark, Rong Li, Weixing Zhao, Ratna Vadlamudi, Patrick Sung, Tyler J. Curiel
Publikováno v:
The Journal of Immunology. 206:67.15-67.15
Tumor PD-L1 mediates non-canonical, intracellular signals including the DNA damage response (DDR), of unclear significance and mechanisms. We show that genetic PD-L1 depletion (PD-L1KO) destabilized the Chk2 protein, a DNA damage response (DDR) facto
Autor:
Anand V Kornepati, Deyi Zhang, Alvaro S Padron, Jacob T Boyd, Yilun Deng, Erica G Osta, Ryan M Reyes, Hailian Shen, Juan Wang, Suresh Kari, Curtis A Clark, Yanfen Hu, Rong Li, Harshita B Gupta, Weixing Zhao, Tyler J Curiel
Publikováno v:
The Journal of Immunology. 204:241.33-241.33
Tumor PD-L1 mediates diverse cell-intrinsic signals that increase cancer pathogenesis including the DNA damage response (DDR). Although immune consequences of tumor-extrinsic PD-L1 blockade are known, novel therapeutic vulnerabilities from inhibiting